

CR1 Is Associated with Amyloid Plaque Burden and Age-Related Cognitive Decline

Lori B. Chibnik, PhD, MPH,^{1,2} Joshua M. Shulman, MD, PhD,^{1,2,3} Sue E. Leurgans, PhD,⁴ Julie A. Schneider, MD, MS,^{4,5} Robert S. Wilson, PhD,⁴ Dong Tran, BS,^{1,2} Cristin Aubin, BS,^{1,2} Aron S. Buchman, MD,⁴ Christopher B. Heward, PhD,⁶ Amanda J. Myers, PhD,^{7,8} John A. Hardy, PhD,^{9,10} Matthew J. Huentelman, PhD,¹¹ Jason J. Corneveaux, BS,¹¹ Eric M. Reiman, MD,^{11,12,13} Denis A. Evans, MD,⁴ David A. Bennett, MD,⁴ and Philip L. De Jager, MD, PhD^{1,2}

Objective: Recently, genome-wide association studies have identified 3 new susceptibility loci for Alzheimer's disease (AD), *CLU*, *CR1*, and *PICALM*. We leveraged available neuropsychological and autopsy data from 2 cohort studies to investigate whether these loci are associated with cognitive decline and AD neuropathology.

Methods: The Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP) are longitudinal studies that enroll nondemented subjects and include annual clinical evaluations and brain donation at death. We evaluated *CR1* (rs6656401), *CLU* (rs11136000), and *PICALM* (rs7110631) in 1,666 subjects. We evaluated associations between genotypes and rate of change in cognitive function as well as AD-related pathology. Lastly, we used pathway analysis to determine whether relationships between single nucleotide polymorphisms and cognitive decline are mediated through AD pathology.

Results: Among our study cohort, the mean years of follow-up were 7.8 for ROS and 4.3 for MAP. Only the *CR1* locus was associated with both global cognitive decline ($p = 0.011$) and global AD pathology ($p = 0.025$). More specifically, the locus affects the deposition of neuritic amyloid plaque ($p = 0.009$). In a mediation analysis, controlling for amyloid pathology strongly attenuated the effect of the *CR1* locus on cognitive decline.

Interpretation: We found that common variation at the *CR1* locus has a broad impact on cognition and that this effect is largely mediated by an individual's amyloid plaque burden. We therefore highlight 1 functional consequence of the *CR1* susceptibility allele and generalize the role of this locus to cognitive aging in the general population.

ANN NEUROL 2011;000:000–000

The 20th century has witnessed a remarkable increase in the number and proportion of older persons, with wide-ranging health consequences, because older persons are at risk for chronic conditions that are relatively rare

among the young. Alzheimer's disease (AD) in particular is among the most common and debilitating age-related conditions, causing progressive amnesia, dementia, and ultimately global cognitive failure and death. Genetic risk

View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.22277

Received Apr 23, 2010, and in revised form Sep 3, 2010. Accepted for publication Sep 17, 2010.

Address correspondence to De Jager, Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB 168C, Boston, MA 02115. E-mail: pdejager@rics.bwh.harvard.edu

From the ¹Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham and Women's Hospital, Boston, MA; ²Program in Medical and Population Genetics, Broad Institute, Cambridge, MA; ³Clinical Investigator Training Program, Beth Israel Deaconess Medical Center–Harvard/MIT Health Sciences and Technology (in collaboration with Pfizer Inc. and Merck & Co.), Chicago, IL; ⁴Rush Alzheimer's Disease Center, Department of Neurological Sciences, Chicago, IL; ⁵Department of Pathology, Rush University Medical Center, Chicago, IL; ⁶Kronos Science Laboratory, Phoenix, AZ; ⁷Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL; ⁸Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute, Tampa, FL; ⁹Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD; ¹⁰Reta Lila Weston Laboratories, Department of Molecular Neuroscience, Institute of Neurology, Queen Square, London, UK; ¹¹Neurogenomics Division, Translational Genomics Research Institute and Arizona Alzheimer's Consortium, Phoenix, AZ; ¹²Banner Alzheimer's Institute and Department of Psychiatry, University of Arizona, Phoenix, AZ; ¹³Department of Psychiatry, University of Arizona, Tucson, AZ.

Additional supporting information can be found in the online version of this article.

factors have long been known to play an important role in the development of AD, but until recently, the only consistently validated susceptibility locus for sporadic late-onset AD was apolipoprotein E (*APOE*), with the $\epsilon 4$ allele conferring an increased risk and the $\epsilon 2$ allele a reduced risk. Using large cohorts of AD cases and controls, 2 independent genome-wide association studies recently identified 3 new loci, complement receptor 1 (*CRI*), clusterin (*CLU*), and the phosphatidylinositol-binding clathrin assembly protein (*PICALM*), with substantial evidence for association with AD,^{1,2} and these loci have now been independently validated.³

The majority of studies seeking to identify genetic variation responsible for AD have been case-control studies comparing persons with disease to those without. However, the dichotomous clinical outcome obscures the reality that AD develops slowly over years, and during this time affected individuals typically progress through a phase called mild cognitive impairment.⁴ In fact, AD neuropathology, consisting of extracellular amyloid plaques and intracellular neurofibrillary tangles, is commonly found at autopsy in individuals without dementia proximate to death, and a substantial proportion of individuals with mild cognitive impairment meet pathological criteria for AD diagnosis.^{5,6} We and others have therefore proposed that intermediate cognitive and pathological traits might complement AD clinical diagnosis as an outcome phenotype for genetic association studies, in part by overcoming confounding due to phenotypic heterogeneity.^{7,8} Indeed, there is now substantial evidence that the *APOE* locus is associated with age-related cognitive decline as well as the accumulation of AD-related pathology in the general population, including individuals without dementia.^{9,10} Furthermore, in earlier work, the association of *APOE* with cognitive decline was shown to be mediated by an intermediate effect on amyloid burden.¹⁰ It has been proposed that similar to *APOE*, the new AD susceptibility loci, *CRI*, *CLU*, and *PICALM*, might directly impact the accumulation of amyloid pathology, perhaps through participation in clearance of the A-beta peptide, which aggregates to form amyloid plaques.^{1,2}

The Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP) are prospectively following >2,300 subjects without dementia at baseline, and include longitudinal clinical evaluation and brain donation at death. In this study, we leverage the wealth of neuropsychiatric and neuropathologic phenotypes available in ROS and MAP to assess whether these loci, like *APOE*, more generally influence age-related cognitive decline. Finally, we perform a functional genetic dissection to evaluate whether associations of these loci with cognition are mediated by an effect on AD neuropathology.

Subjects and Methods

Subjects

Subjects are participants from 2 longitudinal follow-up studies.

The ROS, started in 1994, enrolled Catholic priests, nuns, and brothers, aged ≥ 53 years from about 40 groups in 12 states. Since January 1994, 1,132 participants completed their baseline evaluation, of whom 1,001 were non-Hispanic white. The follow-up rate of survivors exceeds 90%, as does the autopsy rate (481 autopsies of 511 deaths, of whom 457 were non-Hispanic white). Participants were free of known dementia at enrollment, agreed to annual clinical evaluations, and signed both an informed consent and an Anatomic Gift Act form donating their brains at time of death.¹¹ A more detailed description of the ROS can be found in previously published literature.¹¹

The MAP, started in 1997, enrolled older men and women from assisted living facilities in the Chicago area with no evidence on dementia at baseline. Since October 1997, 1,285 participants completed their baseline evaluation, of whom 1,118 were non-Hispanic white. The follow-up rate of survivors exceeds 90%, and the autopsy rate exceeds 80% (336 autopsies of 411 deaths, of whom 320 were non-Hispanic white). Similar to ROS, participants agreed to annual clinical evaluations and signed both an informed consent and an Anatomic Gift Act form donating their brains, spinal cords, and selected nerves and muscles to Rush investigators at the time of death.^{11,12} More detailed descriptions of these studies can be found in previously published literature.^{11,12} Both ROS and MAP were approved by the institutional review board of Rush University Medical Center.

Genotyping

DNA was extracted from whole blood, lymphocytes, or frozen postmortem brain tissue. We used the single nucleotide polymorphisms (SNPs) outlined in recent publications^{1,2} for *CRI* (rs6656401) and *CLU* (rs136000). For *PICALM*, the published SNP (rs3851179) did not pass quality control (QC) in our dataset, so we used a SNP proxy, rs7110631, $r^2 = 0.75$ with rs3851179 in HapMap subjects of European ancestry (<http://hapmap.ncbi.nlm.nih.gov/>). Genotype data for rs6656401 (*CRI*), rs7110631 (*PICALM*), and rs11136000 (*CLU*) were extracted from a genome-wide dataset generated on the Affymetrix Genechip 6.0 platform at the Broad Institute's Center for Genotyping ($n = 1,204$) or the Translational Genomics Research Institute ($n = 674$). These 2 sets of data underwent the same QC analysis in parallel, and QC'ed genotypes were pooled. Only self-declared non-Hispanic Caucasians were genotyped, to minimize population heterogeneity. The PLINK toolkit (<http://pngu.mgh.harvard.edu/~purcell/plink/>) was used to implement our QC pipeline. We applied its standard quality control pipeline for subjects (genotype success rate >95%, genotype-derived gender concordant with reported gender, excess inter-/intra-heterozygosity) and for SNPs (Hardy-Weinberg equilibrium test $p > 1 \times 10^{-6}$; Minor Allele Frequency [MAF] > 0.01, genotype call rate > 0.95; mishap test > 1×10^{-9}) to

these data. In a second step, EIGENSTRAT¹³ was used to identify and remove population outliers using its default parameters. At the conclusion of the QC pipeline, 1,666 individuals were available for analysis; among them, 28 (2%) subjects were missing a *CR1* genotype, 10 (0.6%) were missing a *PICALM* genotype, and 19 (1%) were missing a *CLU* genotype. All 3 SNPs had allele frequencies that satisfied Hardy-Weinberg equilibrium in our data ($p > 0.001$).

Cognitive Outcomes

Our analyses focus on 2 outcome measures of cognition, episodic memory and global cognition. Episodic memory is measured as a composite score of 7 instruments: word memory, recall and recognition list from CERAD; immediate and delayed recall of Story A from the logical memory subset of the Wechsler Memory Scale-Revised; and immediate and delayed recall of the East Boston Story. The global cognition score was a composite of 19 cognitive tests, measuring 5 domains of cognitive function (episodic memory, visuospatial ability, perceptual speed, semantic memory, and working memory) and is described in detail in previously published literature.^{11,12,14–25}

Summary measures were created as previously described^{12,15,23,24} by converting each test into a *Z* score using the mean and SD from baseline evaluation of all participants and averaging the measure for each of the cognitive areas. Summary measures are beneficial for limiting the influence of outliers. For our analysis, at least half of the composite scores must be present for the summary measure to be valid.

Pathology Outcomes

Brain autopsies were performed for nearly all cases at 12 predetermined sites across the United States, including Rush University in Chicago. Autopsy procedures are described in detail in previously published literature.^{11,26,27} We classified persons as having pathologic AD based on intermediate or high likelihood of AD by National Institute on Aging–Reagan criteria using Consortium to Establish a Registry for Alzheimer’s Disease estimates of neuritic plaque density and Braak staging of neurofibrillary pathology,^{28–30} as previously described.¹¹ The quantitative composite AD pathology score was based on counts of neuritic plaques and neurofibrillary tangles, as previously described.^{31,32} We standardized the raw counts by dividing each person’s count by the standard deviation for that particular count and formed a global pathology summary score by averaging the standardized scores. In addition, separate summary measures of neurofibrillary tangles and neuritic and diffuse plaques were created in a similar fashion.

Statistical Analysis

Demographic characteristics of each cohort are described using means and standard deviations for continuous variables and frequency and proportions for categorical variables, including the SNPs of interest. Demographics and genotypic frequencies were compared across studies using 2 independent sample *t* tests and chi-square tests. General linear mixed models adjusting for age at enrollment, years of education, and sex were used to compare

the rate of cognitive decline between genotypes. For all 3 SNPs, we initially used an additive model that examines the affect of each additional risk allele. Because this is a follow-up study to replicate previous findings by Harold et al¹ and Lambert et al,² we imposed a nominal threshold of $p < 0.05$ for significance in the primary analyses for association with global cognitive decline and global pathology in which the default additive model was tested. If a relationship was found at $p < 0.10$, we further examined the relationship using a dominant model comparing the homozygote for the nonrisk allele to the combined heterozygote and homozygote for the risk allele, or using a recessive model comparing the combined homozygote for the nonrisk allele and the heterozygote to the homozygote for the risk allele. We used these mixed models to plot the paths of change in each cognitive measure by genotype for our significant findings. Additional models were also run with further adjustment for *APOE* $\epsilon 4$ allele. As a secondary analysis, logistic regression models adjusted for age at baseline, sex, and education were used to test whether the 3 SNPs were associated with any clinical diagnosis of AD after baseline.

Linear regression and analysis of covariance (ANCOVA) models adjusted for age at death, years of education, and sex were used to assess the relationship between pathology measures and genotypes within the deceased participants. First, a linear regression model was used, and if a significant relationship was found at $p < 0.10$, an ANCOVA model was run where the adjusted mean pathology score is compared between each genotype, the *p* value testing if at least 1 mean is different. Lastly, 2 causal pathway analyses using Cooper’s Local Causal Discovery algorithm³³ are performed by repeating the mixed models adjusting for AD pathology measures to determine whether the relationship between SNP and cognitive decline is mediated by pathology. All results were initially stratified by study and then combined. An interaction term was used to examine possible effect modification over time and determine whether effect sizes vary across study. All tests were performed using SAS software, version 9.2 (SAS Institute, Cary, NC).

Results

Demographics

Genotype data on 791 participants in ROS were available, and 326 (41%) of these subjects had neuropathology data. Genotype data on 875 participants in MAP were available, and 227 (26%) of these subjects had neuropathology data. The mean (\pm standard deviation [SD]) age at enrollment for ROS and MAP participants was 76 (± 7) and 81 (± 7) years, respectively, and the mean (\pm SD) time of follow-up for ROS and MAP was 8 (± 5) and 4 (± 3) years, respectively. Although ROS and MAP differ significantly in demographic information, they do not differ in allele frequencies for the 3 SNPs considered in this analysis ($p > 0.05$ for all SNPs), and none of the interaction analyses were significant (all $p > 0.01$, with 21 tests performed). Because of this, we

TABLE 1: Demographics, Genotypes, Cognitive and Pathology Information^a for Subjects in the ROS and MAP Studies

Characteristic	ROS, n = 791	MAP, n = 875	p	ROS, n = 326	MAP, n = 227	p
Age at enrollment, yr	75.5 ± 7.3	81.0 ± 6.7	<0.0001	79.8 ± 6.9	84.4 ± 5.7	<0.0001
Education, yr	18.1 ± 3.4	14.3 ± 3.2	<0.0001	18.0 ± 3.4	14.5 ± 2.8	<0.0001
Male sex	269 (34%)	240 (27%)	0.004	124 (38%)	83 (37%)	0.725
Deceased	326 (41%)	227 (26%)	<0.0001	87.0 ± 6.9	88.8 ± 5.6	0.0008
Years of follow-up	7.8 ± 4.5	4.3 ± 2.6	<0.0001	6.7 ± 3.8	3.8 ± 2.6	<0.0001
Clinical diagnosis of AD	218 (28%)	186 (21%)	0.0001	135 (41%)	85 (37%)	0.349
Genotypes						
<i>CLU</i> (rs11136000)						
TT	122 (16%)	141 (16%)	0.152	37 (12%)	35 (15%)	0.393
CT	358 (46%)	437 (50%)		167 (54%)	123 (54%)	
CC	296 (38%)	293 (34%)		107 (34%)	69 (30%)	
<i>PICALM</i> (rs7110631)						
CC	63 (8%)	87 (10%)	0.105	29 (9%)	17 (8%)	0.529
CG	352 (45%)	401 (46%)		151 (47%)	104 (47%)	
GG	373 (47%)	380 (44%)		143 (44%)	101 (46%)	
<i>CRI</i> (rs6656401)						
AA	28 (4%)	27 (3%)	0.215	7 (2%)	2 (1%)	0.193
AG	261 (33%)	254 (30%)		112 (35%)	64 (29%)	
GG	493 (63%)	575 (67%)		203 (63%)	152 (70%)	
Cognition at baseline						
Global cognition	0.14 (0.60)	-0.05 (0.64)	<0.0001	0.74 (0.39)	0.770 (0.39)	0.201
Episodic memory	0.16 (0.71)	-0.11 (0.83)	<0.0001	0.75 (0.52)	0.62 (0.51)	0.004
Semantic memory	0.12 (0.72)	0.02 (0.71)	0.004	0.73 (0.54)	0.69 (0.54)	0.334
Working memory	0.07 (0.79)	0.03 (0.73)	0.247	0.59 (0.37)	0.61 (0.42)	0.594
Perceptual speed	0.20 (0.88)	-0.08 (0.88)	<0.0001			
Visuospatial ability	0.11 (0.80)	0.05 (0.79)	0.117			

^an = 553 deceased subjects who passed the genotyping quality control.

ROS = Religious Orders Study; MAP = Rush Memory and Aging Project; AD = Alzheimer disease.

TABLE 2: Relationship between Genes and Change in Global Cognition over Time in the 1,666 ROS and MAP Subjects

	No.	Model 1 ^a		Model 2 ^b	
		Global Cognition	<i>p</i>	Global Cognition	<i>p</i>
<i>CLU</i> (rs11136000)					
Additive		-0.002 (0.005)	0.737	0.001 (0.005)	0.837
<i>PICALM</i> (rs7110631)					
Additive		-0.008 (0.005)	0.099	-0.008 (0.005)	0.103
CC/CG	903	0 (ref)		0 (ref)	
Recessive, GG	753	-0.014 (0.006)	0.034	-0.014 (0.007)	0.033
<i>CR1</i> (rs6656401)					
Additive		-0.015 (0.006)	0.011	-0.014 (0.006)	0.022
GG	1068	0 (ref)		0 (ref)	
Dominant, AG/AA	570	-0.023 (0.007)	0.0008	-0.021 (0.007)	0.002

^aModel 1: adjusted for age at baseline, sex, and years of education.
^bModel 2: adjusted for age at baseline, sex, years of education, and *APOE* $\epsilon 4$. ROS = Religious Orders Study; MAP = Rush Memory and Aging Project; ref = reference.

combined the 2 studies to maximize the statistical power of our primary analyses. However, we also present the results from stratified analyses in Supplemental Tables 1 and 2. In addition, when including a term for study in the models, we saw no change in our results. Thus, we removed the study term from the final models. This approach has been used previously¹¹ and is possible because of the extensive overlap in the information collected prospectively from the 2 cohorts and of their management by a single team of investigators. Demographic information on participants is presented in Table 1. Within the combined cohort, 404 (24%) of the subjects fulfilled criteria for a diagnosis of AD dementia at some point during the follow-up time.

Cognitive Decline

For the *CR1* locus, we see a significantly faster rate of decline in global cognition with each additional risk allele (rs6656401^A) ($p = 0.011$). In secondary analyses, this association with the *CR1* locus is still present if we control for *APOE* $\epsilon 4$ ($p = 0.02$) (Table 2). The effect of the rs6656401^A risk allele may be dominant, as this model returns $p = 0.0008$ for the rate of global cognitive decline. In other secondary analyses, we explored the components of our global cognitive measure and found that the *CR1* locus is associated with a faster decline not only in global cognition but also in episodic memory ($p = 0.003$), semantic memory ($p = 0.05$), perceptual speed ($p = 0.002$), and visuospatial ability ($p = 0.03$) (Supple-

mental Table 3). To illustrate these differences in cognitive trajectory, we plotted the paths of change in global cognition during the first 10 years of observation; we used the dominant model that best fits our data to compare subjects with rs6656401^{AA/AG} genotypes to those with a rs6656401^{GG} genotype (Fig). We can see that, although there is a decline for all subjects, those with any rs6656401^A allele have a steeper decline in global cognition when compared to subjects of the rs6656401^{GG} genotype. Similar figures showing a genotypic model and stratified by study are presented in Supplementary Figures 1 and 2. In addition, we saw a 1.4 (95% confidence interval, 1.1–1.8; $p = 0.006$) times increased time odds of being diagnosed with clinical AD for those with any rs6656401^A allele as compared to subjects with the rs6656401^{GG} genotype (Supplementary Table 4).

For the *PICALM* locus, we saw suggestive evidence of association in the additive model for global cognition, with a faster rate of decline for each additional risk allele (rs7110631^G) ($p = 0.10$). In secondary analyses, the recessive model returns $p = 0.03$ for global cognition (see Table 2). One interesting finding is in the stratified analyses (see Supplementary Table 1). The effect we see at the *PICALM* locus is driven primarily by the MAP cohort. Adjustment for *APOE* $\epsilon 4$ genotype did not change the results in our combined analyses; however, it does affect the MAP-specific analysis. For MAP alone, we see a significant recessive relationship for rs7110631^{GG} versus 7110631^{CC/CG} ($p = 0.009$; see Supplementary Table 1).




FIGURE: Average paths of 10-year change in global cognition and episodic memory for typical persons for *CR1* (rs6656401) using the dominant model. (A) Global cognition ($p = 0.0008$). (B) Episodic memory ($p = 0.003$).

We see no significant relationship between the rate of change in global cognitive performance and the *CLU* locus. Adjustment for *APOE* $\epsilon 4$ genotype did not change the results of the *CLU* loci (see Table 2).

Pathology

We followed up our investigations of cognitive decline with an analysis of traits derived from our autopsy material ($n = 553$). There is an association between the rs6656401^A risk allele in the *CR1* locus and greater AD-related neuropathologic burden on autopsy using our default additive model for the effect of the risk allele ($p = 0.03$) (Table 3). In this case, the small sample size precludes a powerful assessment of the minor (risk) allele homozygote class of subjects (rs6656401^{AA}). Nonetheless, we observe a trend in global neuropathology scores when examining each genotype individually in secondary analyses, with the lowest score seen in rs6656401^{GG} class and increasing scores for each additional risk allele (see Table 3). When breaking down the global pathology score into its components, we see that the significant relationship between the *CR1* locus and pathology is driven

by an effect on diffuse and neuritic plaques ($p = 0.03$ and $p = 0.01$, respectively) but not neurofibrillary tangles ($p = 0.37$). The *APOE* $\epsilon 4$ allele does not modify the associations presented above (data not shown).

On the other hand, no significant differences were seen in analyses of our measure of global pathologic burden with the *CLU* and the *PICALM* loci ($p = 0.98$ and $p = 0.34$ respectively); this continues to hold true when controlling for the *APOE* $\epsilon 4$ allele (data not shown). Exploratory analyses of the components of the global pathology score revealed no association between either loci and measures of amyloid deposition or neurofibrillary tangles (data not shown).

Pathway Analyses

Having independent associations of the *CR1* loci with cognitive decline and AD-related neuropathology, we explored whether these associations were consistent with our putative causal chain linking genetic variation and cognitive dysfunction. For the pathway analyses, we examined cognitive decline as a function of the *CR1* locus and measures of AD pathology in the same model. The results for *CR1* are presented in Table 4. For this analysis, we focus on the slope estimates of cognitive decline and whether controlling for global pathology attenuates the magnitude of the estimate of the risk allele's effect on the rate of global cognitive decline. The slope estimate (standard error) for the association of *CR1* with the rate of global cognitive performance drops from -0.030 (0.016) in the model without global pathology to -0.017 (0.015) (a reduction of 43% in effect size) when we adjust for global pathology. A similar pattern is seen with our estimate of episodic memory decline, which drops from -0.025 (0.018) to -0.008 (0.017) after controlling for global pathology. This represents a 64% decrease in effect size for episodic memory decline (Supplementary Table 5). The decline in the estimates suggests that global pathology is in the pathway between rs6656401^A, the *CR1* risk allele, and decline in global cognitive function. Looking at the components of our global pathology measure, we see that the effect of the rs6656401^A risk allele in the *CR1* locus on cognitive performance is primarily mediated through an effect on neuritic plaques (37% decrease in effect size), with a more modest effect on diffuse plaques (20% decrease in effect size). In our dataset, neurofibrillary tangles have no effect on the correlation between rs6656401^A and cognitive decline (see Table 4).

Discussion

Three novel susceptibility loci have recently been proposed for AD, but additional studies are needed to

TABLE 3: Association between Loci and Global Pathology and Its Components among 553 Deceased Subjects^a

	<u>Global Pathology^b</u>		<u>Diffuse Plaques^b</u>		<u>Neuritic Plaques^b</u>		<u>Neurofibrillary Tangles^b</u>	
	Estimate (SE)	<i>p</i>	Estimate (SE)	<i>p</i>	Estimate (SE)	<i>p</i>	Estimate (SE)	<i>p</i>
<i>CLU</i> (rs11136000)								
β	-0.001 (0.026)	0.975	0.023 (0.035)	0.513	0.017 (0.035)	0.642	-0.089 (0.083)	0.280
<i>PICALM</i> (rs7110631)								
β	0.025 (0.026)	0.343	0.009 (0.035)	0.790	0.039 (0.036)	0.281	0.076 (0.085)	0.372
<i>CRI</i> (rs6656401)								
β	0.073 (0.032)	0.025	0.095 (0.043)	0.029	0.117 (0.044)	0.009	0.093 (0.104)	0.373
Adjusted mean								
GG, n = 355	0.701 (0.397)	0.079	0.664 (0.524)	0.082	0.681 (0.542)	0.029	0.588 (0.394)	0.591
AG, n = 176	0.766 (0.381)		0.743 (0.505)		0.784 (0.519)		0.618 (0.396)	
AA, n = 9	0.895 (0.377)		0.961 (0.641)		1.010 (0.520)		0.561 (0.259)	

^aAdjusted for age at death, sex, and years of education.
^bMeasures are square root of global pathology, diffuse and neuritic plaques, and neurofibrillary tangles.
SE = standard error.

confirm these findings and clarify how the risk alleles within these loci exert their effect. Here, we demonstrate that the risk allele within the *CRI* locus is associated with both a greater burden of AD-related neuropathology and a faster rate of cognitive decline in an aging population that is nondemented at baseline. More specifically, our results suggest that the *CRI* locus has an effect on almost all cognitive domains tested; its effect is not limited to episodic memory. Furthermore, our modeling suggests that this contribution to global cognitive dysfunction is mediated in large part (43% for global cognition and 64% for episodic memory) by an enhanced burden of AD-related neuropathology, particularly amyloid plaques. Nonetheless, our measure of global neuropathology does not fully capture the effect of the *CRI* locus on cognitive function, suggesting that it may also have effects on different, as yet unrecognized mechanisms, or that measures of neuropathology that are molecularly specific may have stronger effects than those seen with histochemistry. Our results are therefore consistent with experiments in vitro and in model organisms that suggest a role for *CRI* in clearance of amyloid plaques.³⁴ These results also establish clear hypotheses relating to the func-

tional consequences of the *CRI* risk allele that can now be explored further in a number of systems and raise the intriguing possibility that this variant may influence the success of different immunotherapies now being tested in AD.

The fact that we have performed these analyses in 2 large prospective cohorts of subjects who were nondemented on enrollment also generalizes the role of *CRI*; this locus, which was discovered in an AD susceptibility scan, may have a broader role in affecting cognitive function in older age. Indeed, we demonstrate that it does not have a predilection for affecting episodic memory; instead, it affects almost all of the cognitive domains that we have tested. It may therefore have a broader role in aging-related neurodegenerative processes. This is also supported by the persistence of the association if we restrict the analysis to cognitive assessments that are obtained from subjects who do not have a diagnosis of AD (see Supplementary Table 4).

The other 2 loci that we tested in this study showed no significant evidence of association with either cognitive function or global pathology in our primary analyses. However, the *PICALM* locus displays suggestive

TABLE 4: Pathway Analysis for Global Pathology, Plaques, and Tangles Effect on the Association between *CR1* and Global Cognition among the 553 Deceased Subjects

<i>CR1</i> (rs6656401)	No.	Global Cognition			
		Model 1 ^a	<i>p</i>		
Model 1					
Additive		−0.026 (0.015)	0.084		
GG	355	0 (ref)			
Dominant, AG/AA	185	−0.030 (0.016)	0.064		
		Model 1 + Global Pathology ^b		Model 1 + Neurofibrillary Tangles ^b	<i>p</i>
Global pathology and neurofibrillary tangles					
Additive		−0.010 (0.014)	0.458	−0.023 (0.014)	0.097
GG	355	0 (ref)		0 (ref)	
Dominant, AG/AA	185	−0.017 (0.015)	0.266	−0.027 (0.015)	0.077
		Model 1 + Diffuse Plaques ^b		Model 1 + Neuritic Plaques ^b	
Plaques					
Additive		−0.020 (0.014)	0.176	−0.015 (0.014)	0.281
GG	355	0 (ref)		0 (ref)	
Dominant, AG/AA	185	−0.024 (0.015)	0.126	−0.019 (0.015)	0.206

^aModel 1: adjusted for age at death, sex, and years of education.
^bModel 1 + pathology measure: adjusted for age at death, sex, years of education, and square root of pathology measure.

evidence of association with cognitive decline. Given our sample size, we can exclude a strong effect of the *PICALM* and *CLU* loci on our outcome measures, but it remains possible that more modest effects exist. These results are consistent with the findings by Guerreiro et al,³⁵ which showed no common coding variants at the *CLU* loci associated with AD. Neither the *CLU* nor the *PICALM* variants are likely to be the causal allele; they are merely the best surrogate marker tested so far. Thus, it is possible the true causal variant in these or the *CR1* locus could have much stronger effects on our outcomes of interest. The *PICALM* analysis was also limited by the unavailability of the reported SNP (rs3851179) in our dataset; instead, we used a surrogate marker, rs7110631, which has an r^2 of 0.75 with rs3851179 in subjects of European ancestry in HapMap (<http://hapmap.ncbi.nlm.nih.gov/>).

In modeling the causal chain of events, we took our analysis further and showed that, when controlling for global pathology, the strength of the relationship between *CR1* and cognitive decline decreases. This suggests that global pathology plays an important role in the causal pathway between *CR1* and cognitive decline.

When limiting our analysis to only those with autopsy data—thus decreasing our sample size—we found only borderline statistical significance with global cognition, which is probably due to limitations in statistical power. Nonetheless, we feel that because (1) we show a significant relationship between *CR1* and the cognition measure when using the larger sample, and (2) the magnitude of the beta estimates clearly decreased when controlling for global pathology, this shows convincing evidence supporting a model in which global pathology mediates the effects of *CR1* on cognition. Further work in model organisms will be necessary to test the hypothesis that alteration of *CR1* function can yield to cognitive dysfunction that is mediated by an effect on amyloid pathology.

Our main analyses considered 3 loci and 2 outcomes, resulting in 6 different tests. Because our primary goal was to replicate previous findings by Lambert et al² and Harold et al,¹ we used a nominal level of significance of 0.05 and did not correct for multiple comparisons. We note, however, that our primary finding that *CR1* is significantly associated with decline in global cognition under the dominant model still holds when

comparing our resulting p value to a Bonferroni-corrected p value of 0.008 ($=0.05/6$).

This study has several strengths. First, both cohorts are rich in data, with high rates of follow-up and autopsy, thus decreasing bias. Second, the analysis was performed on a prospective cohort of older adults, all of whom were cognitively normal at the time of enrollment. Although this design may reduce our power to detect susceptibility genes associated with an earlier age at dementia onset due to differential survivor bias, it permits us to assess associations with cognitive decline and neuropathology unrelated to the subject selection biases in retrospective case-control studies. Third, the standardized nature of both the clinical and pathology procedures produced very similar and reliable measures between the cohorts and allowed us to combine the data and increase our statistical power. Fourth, this study complements and supports findings from a study of an independent group of neuropathologically verified cases and controls, which found associations between *CR1* (as well as *CLU* and *PICALM*) and susceptibility to late-onset AD.³ Finally, we illustrate the advantages of detailed intermediate phenotypes in understanding the functional consequences of common variants associated with AD. In particular, we provide new insights about the neuropathological features underlying the association between *CR1*, age-related cognitive decline, and susceptibility to late-onset AD.

Acknowledgment

This work was supported by National Institutes of Health (NIH) grants R01 AG30146, R01 AG179917, R01 AG15819, P30 AG10161, K08 AG034290, and R01 NS059873. Additional funding was obtained from the NIH Neuroscience Blueprint (U24NS051872), the ENDGAME Consortium (U01HL084744), a National Institute on Aging grant to Carl Cotman (University of California, Irvine, P50 AG23173), National Institute on Aging (K01AG024079), and the state of Arizona.

We thank the participants in the Religious Orders Study and the Memory and Aging Project and the staff of the Rush Alzheimer's Disease Center and the Broad Institute.

Potential Conflicts of Interest

A.J.M. is supported by National Institute on Aging grant R01 AG034504 and the Johnnie B. Byrd Institute. J.A.H. has done consultancy work for and received honoraria from Eisai and MerckSerono, and would like to thank the Verum foundation. M.J.H., J.J.C., and E.M.R. are supported by grants from Kronos Life Sciences Laboratories, the National Institute on Aging (Arizona Alzhei-

mer's Disease Center P30 AG19610, RO1 AG023193, Mayo Clinic Alzheimer's Disease Center P50 AG16574, and Intramural Research Program), the National Alzheimer's Coordinating Center (U01 AG016976), and the state of Arizona. J.M.S. is a participant in the Clinical Investigator Training Program, a fellowship administered by Beth Israel Deaconess Medical Center–Harvard/Massachusetts Institute of Technology Health Sciences and Technology, in collaboration with Pfizer Inc. and Merck & Co. J.A.S. has done consultancy work for AVID Radiopharmaceuticals, has provided expert testimony for Spina, McGuire, & Okal, PC and Michael Best & Friedrich LLP, and has received payment for manuscript preparation from BMJ Publishing Group, Limited. P.L.D.J. has received honoraria from Biogen IDEC. R.S.W., C.B.H., and D.A.B. work for Kronos Life Sciences Laboratories.

References

1. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at *CLU* and *PICALM* associated with Alzheimer's disease. *Nat Genet* 2009;41:1088–1093.
2. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at *CLU* and *CR1* associated with Alzheimer's disease. *Nat Genet* 2009;41:1094–1099.
3. Huentelman M. Association of *CR1*, *CLU*, and *PICALM* with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. *Hum Mol Genet* 2010;19:3295–3301.
4. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med* 2004;256:183–194.
5. Markesbery WR, Schmitt FA, Kryscio RJ, et al. Neuropathologic substrate of mild cognitive impairment. *Arch Neurol* 2006;63:38–46.
6. Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnesic mild cognitive impairment. *Arch Neurol* 2006;63:665–672.
7. Bennett DA, De Jager PL, Leurgans SE, Schneider JA. Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. *Neurology* 2009;72:1495–1503.
8. Reitz C, Mayeux R. Endophenotypes in normal brain morphology and Alzheimer's disease: a review. *Neuroscience* 2009;164:174–190.
9. Reiman EM, Chen K, Alexander GE, et al. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. *Proc Natl Acad Sci U S A* 2005;102:8299–8302.
10. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. *Proc Natl Acad Sci U S A* 2009;106:6820–6825.
11. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. *Neurology* 2006;66:1837–1844.
12. Bennett DA, Schneider JA, Buchman AS, et al. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. *Neuroepidemiology* 2005;25:163–175.
13. Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* 2006;38:904–909.

14. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke* 1993;24:35–41.
15. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. *Neurology* 2002;59:198–205.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;12:189–198.
17. Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. *Arch Neurol* 2003;60:729–736.
18. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). *Mov Disord* 1992;7:2–13.
19. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 1984;34:939–944.
20. Robins LN, Helzer JE, Ratcliff KS, Seyfried W. Validity of the diagnostic interview schedule, version II: DSM-III diagnoses. *Psychol Med* 1982;12:855–870.
21. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. *Neurology* 1993;43:250–260.
22. Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. *Neurology* 1994;44:609–614.
23. Wilson RS, Barnes LL, Krueger KR, et al. Early and late life cognitive activity and cognitive systems in old age. *J Int Neuropsychol Soc* 2005;11:400–407.
24. Wilson RS, Beckett LA, Barnes LL, et al. Individual differences in rates of change in cognitive abilities of older persons. *Psychol Aging* 2002;17:179–193.
25. Wilson RS, Bennett DA. Assessment of cognitive decline in old age with brief tests amenable to telephone administration. *Neuroepidemiology* 2005;25:19–25.
26. Bennett DA, Schneider JA, Bienias JL, et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. *Neurology* 2005;64:834–841.
27. Schneider JA, Wilson RS, Bienias JL, et al. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. *Neurology* 2004;62:1148–1155.
28. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. *Neurobiol Aging* 1997;18:S1–S2.
29. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* 1991;82:239–259.
30. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 1991;41:479–486.
31. Bennett DA, Schneider JA, Tang Y, et al. The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study. *Lancet Neurol* 2006;5:406–412.
32. Bennett DA, Wilson RS, Schneider JA, et al. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. *Neurology* 2003;60:246–252.
33. Cooper G. A simple constraint-based algorithm for efficiently mining observational databases for causal relationships. *Data Min Knowl Discov* 1997;1:203–224.
34. Wyss-Coray T, Yan F, Lin AH, et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. *Proc Natl Acad Sci U S A* 2002;99:10837–10842.
35. Guerreiro RJ, Beck J, Gibbs JR, et al. Genetic variability in CLU and its association with Alzheimer's disease. *PLoS One* 2010;5:e9510.